Log in
Enquire now
‌

US Patent 9540367 Deuterated baricitinib

Patent 9540367 was granted and assigned to Concert Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Concert Pharmaceuticals
Concert Pharmaceuticals
0
Current Assignee
Concert Pharmaceuticals
Concert Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
95403670
Patent Inventor Names
Roger D. Tung0
Date of Patent
January 10, 2017
0
Patent Application Number
144220490
Date Filed
August 15, 2013
0
Patent Citations Received
‌
US Patent 11992490 Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
0
‌
US Patent 11918581 Combination therapy comprising JAK pathway inhibitor and rock inhibitor
0
Patent Primary Examiner
‌
Susanna Moore
0
Patent abstract

The present invention in one embodiment provides a compound of Formula I:

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9540367 Deuterated baricitinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.